Invesco’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $826K | Buy |
220,205
+158,650
| +258% | +$606K | ﹤0.01% | 3021 |
|
|
2026
Q1 | $289K | Buy |
61,555
+39,579
| +180% | +$201K | ﹤0.01% | 3355 |
|
|
2025
Q4 | $93.6K | Sell |
21,976
-450
| -2% | -$1.71K | ﹤0.01% | 3644 |
|
|
2025
Q3 | $71.5K | Buy |
22,426
+8,255
| +58% | +$18.6K | ﹤0.01% | 3722 |
|
|
2025
Q2 | $32.2K | Buy |
+14,171
| New | +$22.8K | ﹤0.01% | 3745 |
|
|
2024
Q4 | – | Sell |
-37,464
| Closed | -$44.2K | – | 3767 |
|
|
2024
Q3 | $44.2K | Buy |
37,464
+14,370
| +62% | +$18.3K | ﹤0.01% | 3698 |
|
|
2024
Q2 | $28.2K | Buy |
+23,094
| New | +$46K | ﹤0.01% | 3862 |
|
|
2023
Q4 | – | Sell |
-22,071
| Closed | -$28.5K | – | 3842 |
|
|
2023
Q3 | $28.5K | Buy |
22,071
+2,613
| +13% | +$4.11K | ﹤0.01% | 3837 |
|
|
2023
Q2 | $33.5K | Buy |
19,458
+6,393
| +49% | +$10.6K | ﹤0.01% | 3840 |
|
|
2023
Q1 | $19.7K | Sell |
13,065
-396
| -3% | -$895 | ﹤0.01% | 3816 |
|
|
2022
Q4 | $21.5K | Buy |
+13,461
| New | +$19.9K | ﹤0.01% | 3965 |
|
|
2022
Q2 | – | Sell |
-23,628
| Closed | -$63K | – | 4059 |
|
|
2022
Q1 | $63K | Buy |
23,628
+729
| +3% | +$2.8K | ﹤0.01% | 3907 |
|
|
2021
Q4 | $99K | Sell |
22,899
-7,276
| -24% | -$42.6K | ﹤0.01% | 3907 |
|
|
2021
Q3 | $154K | Buy |
30,175
+4,850
| +19% | +$26K | ﹤0.01% | 3865 |
|
|
2021
Q2 | $161K | Buy |
25,325
+12,657
| +100% | +$98.6K | ﹤0.01% | 3830 |
|
|
2021
Q1 | $98K | Sell |
12,668
-14,366
| -53% | -$114K | ﹤0.01% | 3760 |
|
|
2020
Q4 | $177K | Buy |
27,034
+5,552
| +26% | +$39.7K | ﹤0.01% | 3560 |
|
|
2020
Q3 | $143K | Sell |
21,482
-494
| -2% | -$3.66K | ﹤0.01% | 3534 |
|
|
2020
Q2 | $183K | Sell |
21,976
-2,317
| -10% | -$21.5K | ﹤0.01% | 3498 |
|
|
2020
Q1 | $186K | Buy |
+24,293
| New | +$169K | ﹤0.01% | 3424 |
|
|
2019
Q3 | – | Sell |
-53,241
| Closed | -$597K | – | 3685 |
|
|
2019
Q2 | $597K | Sell |
53,241
-6,713
| -11% | -$70.4K | ﹤0.01% | 3259 |
|
|
2019
Q1 | $645K | Sell |
59,954
-12,520
| -17% | -$185K | ﹤0.01% | 3208 |
|
|
2018
Q4 | $1.09M | Sell |
72,474
-15,677
| -18% | -$233K | ﹤0.01% | 2923 |
|
|
2018
Q3 | $1.63M | Sell |
88,151
-371,146
| -81% | -$8.46M | ﹤0.01% | 2895 |
|
|
2018
Q2 | $10.5M | Sell |
459,297
-15,201
| -3% | -$388K | ﹤0.01% | 1631 |
|
|
2018
Q1 | $13.5M | Sell |
474,498
-38,496
| -8% | -$1.1M | 0.01% | 1372 |
|
|
2017
Q4 | $10.8M | Buy |
512,994
+379,078
| +283% | +$7.86M | ﹤0.01% | 1533 |
|
|
2017
Q3 | $2.43M | Buy |
133,916
+12,233
| +10% | +$191K | ﹤0.01% | 2429 |
|
|
2017
Q2 | $1.89M | Buy |
121,683
+90,758
| +293% | +$1.37M | ﹤0.01% | 2598 |
|
|
2017
Q1 | $534K | Buy |
+30,925
| New | +$407K | ﹤0.01% | 3310 |
|
Other funds holding CTMX
KCM
PA
VA
Invesco's CTMX Position: Q2 2026 in Review
Invesco increased its CytomX Therapeutics (CTMX) stake by 258% in Q2 2026, buying an estimated $606K and bringing the position to 220,205 shares worth $826K. The position accounts for ﹤0.01% of the portfolio, ranked #3021.
Invesco first reported a position in CTMX in Q1 2017 and has held it in 30 quarters since. The position peaked at $13.5M in Q1 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.
- Invesco held 220,205 shares of CytomX Therapeutics worth $826K as of Q2 2026.
- Invesco bought 158,650 CytomX Therapeutics shares in Q2 2026, an estimated $606K.
- CytomX Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3021 holding.
- Invesco first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 30 quarters since.
- Invesco's CytomX Therapeutics position peaked at $13.5M in Q1 2018.
- 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.
Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.